Optimi Health (OPTH)
Manufactures regulated psilocybin and MDMA products for therapeutic-access and clinical-research channels.
$5.09
After hours+0.12 (+2.41%)
At close$4.97(+2.69%)
In millions of USD, except per-share figures
| In millions | Q4 FY23Sep 2023 | Q1 FY24Dec 2023 | Q2 FY24Mar 2024 | Q3 FY24Jun 2024 | Q4 FY24Sep 2024 | Q1 FY25Dec 2024 | Q2 FY25Mar 2025 | Q3 FY25Jun 2025 | Q4 FY25Sep 2025 | Q1 FY26Dec 2025 | Q2 FY26Mar 2026 | Q3 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Research & development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Operating income | −1 | −1 | −1 | −1 | −2 | −1 | −1 | −1 | −2 | −1 | −1 | −2 |
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | −1 | 0 | −1 | 0 | 0 | 0 |
| Income before tax | −1 | −1 | −1 | −1 | −2 | −1 | 0 | −1 | −1 | — | −2 | −2 |
| Net income from continuing operations | −1 | −1 | −1 | −1 | −2 | −1 | 0 | −1 | −1 | — | −2 | −2 |
| Other adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −1 | −1 | −1 | −2 | −2 | −1 | 0 | −1 | −1 | — | −2 | −2 |
| EPS, basic | $0.00 | −$0.01 | −$0.49 | −$0.02 | $0.00 | −$0.42 | −$0.06 | −$0.28 | −$0.42 | −$0.48 | −$0.49 | −$0.39 |
| EPS, diluted | $0.00 | −$0.01 | −$0.49 | −$0.02 | $0.00 | −$0.42 | −$0.06 | −$0.28 | −$0.42 | −$0.48 | −$0.49 | −$0.39 |
| Weighted average shares, basic | 0 | 86 | 3 | 90 | 0 | 3 | 3 | 3 | 3 | 3 | 3 | 4 |
| Weighted average shares, diluted | 0 | 86 | 3 | 90 | 0 | 3 | 3 | 3 | 3 | 3 | 3 | 4 |
| EBITDA | −1 | −1 | −1 | −1 | −1 | −1 | 0 | −1 | −1 | −1 | −1 | −1 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −1 | −1 | −1 | −1 | −2 | −1 | 0 | −1 | −1 | −1 | −1 | −2 |